

1 **Genomic Landscape of Lymphatic Malformations: A Case Series and Response**  
2 **to the PI3K $\alpha$  Inhibitor Alpelisib in an N-of-One Clinical Trial**

3 Montaser F. Shaheen<sup>1,2,\*,\dagger</sup>, Julie Y. Tse<sup>3,\*,\dagger</sup>, Ethan S. Sokol<sup>3</sup>, Margaret Masterson<sup>4,5</sup>,  
4 Pranshu Bansal<sup>6,7</sup>, Ian Rabinowitz<sup>6,7</sup>, Christy A. Tarleton<sup>6,8</sup>, Andrey S. Dobroff<sup>6,8</sup>, Tracey  
5 L. Smith<sup>9,10</sup>, Th  r  se J. Bocklage<sup>6,11</sup>, Brian K. Mannakee<sup>1,12</sup>, Ryan N. Gutenkunst<sup>1,13</sup>,  
6 Joyce E. Bischoff<sup>14,15</sup>, Scott A. Ness<sup>6,8</sup>, Gregory M. Riedlinger<sup>4,16</sup>, Roman Groisberg<sup>4,17</sup>,  
7 Renata Pasqualini<sup>9,10,\dagger</sup>, Shridar Ganesan<sup>4,17,\*,\ddagger</sup>, and Wadih Arap<sup>6,18,\*,\ddagger</sup>

8 <sup>1</sup>University of Arizona Cancer Center; Tucson, AZ 85719.

9 <sup>2</sup>Division of Hematology/Oncology, Department of Medicine, University of Arizona College of  
10 Medicine; Tucson, AZ 85724.

11 <sup>3</sup>Foundation Medicine, Inc.; Cambridge, MA 02141.

12 <sup>4</sup>Rutgers Cancer Institute of New Jersey; New Brunswick, NJ 08901.

13 <sup>5</sup>Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; New Brunswick, NJ  
14 08901.

15 <sup>6</sup>University of New Mexico Comprehensive Cancer Center; Albuquerque, NM 87131.

16 <sup>7</sup>Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico  
17 School of Medicine; Albuquerque, NM 87131.

18 <sup>8</sup>Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico  
19 School of Medicine; Albuquerque, NM 87131.

20 <sup>9</sup>Rutgers Cancer Institute of New Jersey; Newark, NJ 07103.

21 <sup>10</sup>Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical  
22 School; Newark, NJ 07103.

23 <sup>11</sup>Department of Pathology, University of Kentucky College of Medicine and Markey Cancer  
24 Center; Lexington, KY 40536.

25 <sup>12</sup>Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public  
26 Health, University of Arizona; Tucson, AZ 85724.

27 <sup>13</sup>Department of Molecular and Cellular Biology, College of Science, University of Arizona;  
28 Tucson, AZ 85721.

29 <sup>14</sup>Vascular Biology Program, Boston Children's Hospital; Boston, MA 02115.

30 <sup>15</sup>Department of Surgery, Harvard Medical School; Boston, MA 02115.

31 <sup>16</sup>Department of Pathology, Rutgers Robert Wood Johnson Medical School; New Brunswick, NJ  
32 08901.

33 <sup>17</sup>Division of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson  
34 Medical School; New Brunswick, NJ 08901.

35 <sup>18</sup>Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical  
36 School, Newark, NJ 07103.

37 \*Corresponding authors. Correspondence should be addressed to Dr. Wadih Arap, 185 South  
38 Orange Ave. B-1121, Newark, NJ 07103, phone: 973-972-0366, E-mail:  
39 [wadih.arap@rutgers.edu](mailto:wadih.arap@rutgers.edu); Dr. Montaser F. Shaheen, E-mail: [shaheenm@email.arizona.edu](mailto:shaheenm@email.arizona.edu); Dr.  
40 Julie Y. Tse, E-mail: [jtse@foundationmedicine.com](mailto:jtse@foundationmedicine.com); or Dr. Shridar Ganesan, E-mail:  
41 [ganesash@cinj.rutgers.edu](mailto:ganesash@cinj.rutgers.edu).

42 †Montaser F. Shaheen and Julie Y. Tse contributed equally to this work.

43 ‡Renata Pasqualini, Shridar Ganesan, and Wadih Arap jointly supervised this work.

44  
45 **Conflict of interest statement:** M.F.S. reports personal fees from Illumina, BMS, and Qiagen  
46 (outside of the submitted work). J.Y.T., E.S.S., and B.K.M. are employees of Foundation  
47 Medicine, Inc., a wholly owned subsidiary of Roche, and they own equity in Roche. S.G. has  
48 consulting agreements with Merck, Roche, Novartis, Foundation Medicine, EQRX, Foghorn

49 Therapeutics, Silagene, and KayoThera and owns equity in Silagene; his spouse is an  
50 employee of Merck and owns equity in Merck (all outside of the submitted work). R.G. reports  
51 research funding/grant support for clinical trials (to his institution) from Regeneron, BMS,  
52 Merck/EMD Serano, Amgen, Roche/Genentech, Philogen; consulting/advisory board fees from  
53 Regeneron; and speaker fees for Deciphera (all outside of the submitted work). R.P. and W.A.  
54 are founders and equity stockholders of PhageNova Bio and of MBrace Therapeutics; R.P. is a  
55 paid consultant for PhageNova Bio and MBrace Therapeutics and also serves as the Chief  
56 Scientific Officer of PhageNova Bio and a member of the board for MBrace Therapeutics (all  
57 outside of the submitted work). For R.G., R.P., S.G., and W.A., these arrangements are  
58 managed in accordance with the established institutional conflict of interest policies of Rutgers,  
59 The State University of New Jersey. The remaining authors have declared no potential  
60 competing interests.

61

62

63 **KEYWORDS:** lymphatic malformations, genomics, NGS, PI3K $\alpha$

64

65

66 **ABSTRACT**

67 **Background:** Lymphatic malformations (LMs) often pose treatment challenges due to a large  
68 size or a critical location that could lead to disfigurement, and there are no standardized  
69 treatment approaches for either refractory or unresectable cases.

70 **Methods:** We examined the genomic landscape of a patient cohort of LMs (n=30 cases) that  
71 underwent comprehensive genomic profiling (CGP) using a large-panel next generation  
72 sequencing (NGS) assay. Immunohistochemical analyses were completed in parallel.

73 **Results:** These LMs had low mutational burden with hotspot *PIK3CA* mutations and *NRAS*  
74 mutations being most frequent, and mutually exclusive. All LM cases with Kaposi sarcoma-like  
75 (kaposiform) histology had *NRAS* mutations. One index patient presented with subacute  
76 abdominal pain and was diagnosed with a large retroperitoneal lymphatic malformation  
77 harboring a somatic *PIK3CA* gain-of-function mutation (H1047R). The patient achieved a rapid  
78 and durable complete response to the PI3K $\alpha$  inhibitor alpelisib within the context of a  
79 personalized N-of-1 clinical trial (NCT03941782). In translational correlative studies, canonical  
80 PI3K $\alpha$  pathway activation was confirmed by immunohistochemistry and human LM-derived  
81 lymphatic endothelial cells carrying an allele with an activating mutation at the same locus were  
82 sensitive *in vitro* to alpelisib in a concentration-dependent manner.

83 **Conclusions:** Our findings establish that LM patients with conventional or kaposiform histology  
84 have distinct, yet targetable, driver mutations.

85 **Funding:** R.P. and W.A. are supported by awards from the Levy-Longenbaugh Fund. S.G. is  
86 supported by awards from the Hugs for Brady Foundation. This work has been funded in part by  
87 the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center  
88 (CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the



89 Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science  
90 Foundation via Graduate Research Fellowship DGE-1143953.

91 **Clinical trial number:** NCT03941782

92

93

94

## 95 INTRODUCTION

96 Vascular anomalies, including lymphatic malformations (LMs), are usually diagnosed in children  
97 or young individuals and they can present as either isolated lesions or as part of somatic or  
98 congenital syndromes. In general, LMs are managed by sclerotherapy, laser, or surgical  
99 interventions when there is an indication for therapy<sup>1</sup>. In certain cases, LMs can attain large  
100 sizes or involve critical locations, which poses treatment challenges such as the possibility of  
101 disfigurement. Genomic sequencing has demonstrated a somatic clonal origin for a number of  
102 non-malignant growth conditions including LMs. Activating *PIK3CA* mutations have been  
103 reported in most pediatric patients with isolated or syndromic LMs<sup>2</sup>. This finding has led to the  
104 use of mammalian target of rapamycin (mTOR) inhibitors for systemic therapy of unresectable  
105 LMs, given that mTOR is a molecule downstream of the PI3K pathway<sup>3</sup>. However, only a  
106 subset of patients responded, and the treatment can have substantial side-effects. PI3K  
107 inhibitors have also been reported as being effective in treatment of children with diseases in  
108 the *PIK3CA*-related Overgrowth Spectrum (termed PROS), but the efficacy of alpelisib in  
109 isolated sporadic LMs is not at all clear. Similarly, it is not as yet clear which oncogenic drivers,  
110 if any, are present in LMs with wild-type *PIK3CA* alleles.

111

112 To define the spectrum of genomic alterations and lesions present in LMs, here we have  
113 analyzed a patient cohort of LMs (n=30 cases) assayed by clinical-grade genomic sequencing.  
114 Pathogenic activating mutations in *PIK3CA* and *NRAS* were the most common genetic  
115 alterations found. Strikingly, the *PIK3CA* and *NRAS* mutations were mutually exclusive with  
116 *NRAS* mutations being greatly enriched in LMs with kaposiform morphology. We have also  
117 performed an N-of-1 trial of the PI3K $\alpha$  inhibitor alpelisib in a young man with an activating  
118 *PIK3CA* point mutation, presenting with a giant (unresectable) retroperitoneal and pancreatic

119 LM, who had a dramatic and prolonged response to the drug lasting years, and we present  
120 confirmatory translational correlates *in vitro*.

121

122

## 123 **RESULTS**

### 124 **Mutational Landscape and Histopathology of Lymphatic Malformations**

125 A set of thirty cases of LMs (from 30 individual patients) were assayed with genomic profiling at  
126 Foundation Medicine, Inc. (Cambridge, MA). Twenty-eight cases were sequenced using hybrid-  
127 capture next-generation sequencing (NGS) targeting exons of 300+ cancer genes and select  
128 introns of 36 genes. Two other cases were sequenced using hybrid-capture based DNA  
129 sequencing targeting exons of 406+ cancer genes and select introns of 36 genes, plus RNA  
130 sequencing of 265 genes for rearrangement calling. The patients were predominantly pediatric  
131 age (median 9-year-old; range, 1-year-old to 45-years-old), with a slight female predominance  
132 (17 females, 57% to 13 males, 43%). Seven patients had a documented history of prior  
133 treatment with an mTOR inhibitor, such as sirolimus. Seven patients (23%) carried clinical  
134 diagnoses of overgrowth syndromes including Congenital Lipomatous Overgrowth with  
135 Vascular, Epidermal, and Skeletal anomalies (termed CLOVES), Klippel-Trenaunay Syndrome,  
136 and PTEN-like hamartoma syndrome. Twelve patients (40%) had multifocal disease and eight  
137 patients had involvement of bone and visceral sites (**Table 1**). Expert histopathological review  
138 showed that only four (13%) had kaposiform morphology, while 26 (87%) had conventional  
139 histology. The estimated histopathologic purity ranged from 10% to 70% (median 20%).

140

141

142

143

144

145

**Table 1: Clinical and histological features of lymphatic malformation cohort**

Patient	Age range (years)	Sex	Clinical syndrome	Localized vs. multifocal	Location of LM(s)	Specimen type	LM histology	<i>PIK3CA</i> or <i>NRAS</i> alteration	% VAF
1	6-10	M	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E542K	14
2	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E542K	7
3	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	11
4	16-20	M		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	4
5	16-20	M		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047L	4
6	6-10	F	Klippel-Trenaunay	Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	9
7	6-10	M		Localized	Visceral	Core biopsy	Conventional	<i>PIK3CA</i> E545K	7
8	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> C420R	5
9	21-25	M		Localized	Visceral	Incisional biopsy	Conventional	<i>PIK3CA</i> H1047R	4
10	16-20	F	PTEN-like hamartoma	Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	3
11	0-5	F	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E545K	12
12	0-5	M		Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	2
13	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E542K	6
14	0-5	M		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	5
15	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E545K	1
16	11-15	F		Multifocal	Visceral	Excision	Conventional	<i>PIK3CA</i> C420R	14
17	0-5	F	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> C420R	38
18	16-20	F	CLOVES	Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E453K	32
19	6-10	F	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047L	15
20	6-10	M		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	5
21	6-10	F		Multifocal	Visceral	Excision	Kaposiform	<i>NRAS</i> Q61R	5
22	6-10	M		Multifocal	Superficial soft tissues	Excision	Kaposiform	<i>NRAS</i> Q61R	5
23	6-10	F		Multifocal	Visceral	Excision	Kaposiform	<i>NRAS</i> Q61R	1
24	41-45	M		Multifocal	Visceral	Core biopsy	Conventional	<i>NRAS</i> Q61R	6
25	6-10	F		Localized	Superficial soft tissues	Core biopsy	Kaposiform	<i>NRAS</i> Q61R	14
26	16-20	M		Multifocal	Superficial soft tissues	Excision	Conventional	WT	NA
27	21-25	M		Localized	Bone	Core biopsy	Conventional	WT	NA
28	0-5	M		Multifocal	Superficial soft tissues	Excision	Conventional	WT	NA
29	11-15	F		Localized	Superficial soft tissues	Excision	Conventional	WT	NA
30	6-10	F		Localized	Superficial soft tissues, bone	Biopsy	Conventional	WT	NA

146


147

148

Key: VAF – variant allele frequency of *PIK3CA* or *NRAS*; CLOVES – congenital lipomatous overgrowth, vascular anomalies, epidermal nevi, and skeletal anomalies; NA - not applicable

149 Mutational profiling showed that these LMs had uniformly low mutational burden (median, zero  
150 mutations/Mb; range, 0-2.6 mutations/Mb), and none had evidence of microsatellite instability.  
151 The most common mutations were activating mutations in *PIK3CA*, seen in 20 (67%), and  
152 activating *NRAS* mutations, seen in 5 (17%) (**Figure 1A, B**). The *PIK3CA* mutations included  
153 both hotspot mutations in the helical domain and in the kinase domain<sup>4</sup>. The *NRAS* mutations all  
154 altered the known hotspot at residue glutamine 61 (Q61) in the phosphorylation binding loop.  
155 Of the five patients (17%) with no alterations in *PIK3CA* and *NRAS*, one case (Patient #29;  
156 **Table 1**) had an activating *GOPC-ROS1* fusion (**Figure 1C**) with a *ROS1* missense point  
157 mutation. Similar *GOPC-ROS1* fusions have been reported in pediatric gliomas in the setting of  
158 microdeletion of chromosome 6q22<sup>5</sup> and, have also been found in adult lung cancer<sup>6</sup>.

159  
160 The variant allele frequencies (VAF) of the *PIK3CA* and *NRAS* mutations were relatively low  
161 (median, 6%; range, 1-38%), compatible with relatively low histopathologic estimated  
162 percentage of tumor nuclei (%TN) to overall cellular nuclei (median, 20%; range, 10 to 70%).  
163 These results suggest that the *PIK3CA* and *NRAS* mutations were likely clonal, but in the  
164 setting of relatively low tumor purity in the specimens.



165  
 166 **Fig. 1. Mutational Landscape and Histopathology of Lymphatic Malformations.** (A) Oncoprint  
 167 showing mutational landscape of 30 LM samples sequenced. (B) Lollipop plot showing spectrum of  
 168 *PIK3CA* and *NRAS* mutations in this cohort. (C) Schema showing details of *GOPC-ROS1* fusion identified  
 169 in an *NRAS* and *PIK3CA* wild-type LM. (D) Representative histologic images for LMs with conventional  
 170 and kaposiform histology. The relative frequencies of *PIK3CA* and *NRAS* mutations in the two histologic  
 171 variants are plotted.

172

## 173 **Enrichment of *NRAS* Mutations in Lymphatic Malformations with Kaposiform Features**

174 Histopathological analysis of the lesions by an expert dermatopathologist (J.Y.T.) identified that  
175 four (13%) of the analyzed specimens had kaposiform histopathological features with highly  
176 cellular, clustered, or sheet-like, proliferation of spindled lymphatic cells admixed with dilated  
177 thin-walled lymphatic vessels (**Figure 1D**). The remaining 26 lesions (87%) had conventional  
178 histopathological features of classic LM, with proliferation of dilated, thin-walled lymphatic  
179 vessels with or without luminal proteinaceous material. Lymphatic phenotype of the cells was  
180 confirmed by immunopositivity for PROX1 or D2-40. Of the conventional histology LM cases  
181 (n=26), twenty (77%) had a *PIK3CA* mutation, while one (4%) had a *NRAS* mutation, and five  
182 (19%) were wild-type for both genes, including a single-case with a *GOPC-ROS1* genetic  
183 fusion. Notably, all four cases of LM with kaposiform features had an activating *NRAS* mutation,  
184 consistent with enrichment of *NRAS* mutation (p=0.00018) and lack of *PIK3CA* mutation in this  
185 histology (p=0.0046). The lone *NRAS*-mutant LM with conventional histology was a small core  
186 needle-biopsy specimen of a large visceral tumor, raising the possibility that the histopathologic  
187 features of the sampled tissue may not have been representative of the entire lesion due to the  
188 histologic spatial heterogeneity often seen in LMs with kaposiform histology. Additional  
189 histopathologic features were assessed, including altered adipose tissue, muscularized blood  
190 vessels, vascular endothelial cell atypia, and inflammation; no statistical significance was  
191 identified between the four *NRAS*-mutant LM cases and the remainder of the patient cohort.

192

## 193 **Case Report and N-of-One Clinical Trial Results**


194 One of the conventional histology LMs was a male (age range 21-25 years) with no significant  
195 medical or family history who presented with subacute abdominal pain (Patient #9, **Table 1**). He  
196 was hospitalized and his exam revealed a distended abdomen that was tender to palpation. A  
197 computed tomography exam revealed a large solid mass based on the retroperitoneal area and

198 the pancreas (**Figure 2A**), and a neoplastic process was suspected. A core needle biopsy was  
199 attempted but yielded no definitive tissue diagnosis. An open laparoscopic surgical biopsy was  
200 performed and revealed a vascular tumor with features of a giant retroperitoneal and pancreatic  
201 LM (**Figure 2 D,E**). After discussing a surgical approach, the patient and the surgical team  
202 decided not to proceed due to the complexity of surgical resection and associated risks. The  
203 tissue was submitted for NGS to identify potential biomarkers for targeted therapy.

204  
205 Clinical grade sequencing of the biopsy sample from Patient #9 uncovered a single point  
206 activating mutation in *PIK3CA* (H1047R). All other genes in the panel were wild-type except for  
207 another unit of the PI3K complex (*PIK3C2B*) that showed a variant (R458Q) of unknown  
208 significance (VUS). To confirm activation of the PI3K $\alpha$  pathway, we performed  
209 immunohistochemistry (IHC) staining of the downstream targets (P-AKT and P-6S), and, as  
210 predicted, these phosphorylation events were detected in the lining cells of the abnormal  
211 lymphatic channels (**Figure 2 F,G**).

212  
213 Based on the genomic profile, we designed and offered this young man a single-patient (N-of-  
214 One) personalized clinical trial of the PI3K $\alpha$  inhibitor alpelisib (NCT03941782), which at the time  
215 was still investigational (non-FDA approved). Screening procedures included an  
216 echocardiogram that revealed an ejection fraction (EF) of 47%. A cardiac MRI confirmed a low  
217 EF with no infiltrative process or other abnormalities. Paradoxically, the patient was completely  
218 asymptomatic from a cardiac standpoint and he was able to run two miles on a daily basis. We  
219 hypothesized that the decreased EF, in the absence of accompanying clinical signs or  
220 symptoms of heart failure, was likely artefactual due to hemodynamic changes related to the  
221 very large circulatory volume sequestration in his abdomen.





222

223 **Fig. 2. Imaging and histological analysis of LM patient. (A)** Baseline CT abdomen scan at the time of  
224 presentation demonstrating a large retroperitoneal/pancreatic LM. **(B)** CT abdomen scan 6 weeks after  
225 the initiation of alpelisib. **(C)** CT abdomen scan one year into the trial. **(D and E)** Hematoxylin and eosin  
226 (H&E)-stained photomicrographs of the LM showing dilated lymphatic channels percolating through  
227 visceral fat and associated patchy lymphocytic inflammation (4x and 10x, respectively). **(F)**  
228 Immunohistochemistry utilizing an anti-P-6S antibody demonstrates PI3K $\alpha$  pathway activation within the  
229 channels' lining cells. **(G)** Anti-P-AKT positivity in the lining endothelium of lymphatic channels as well.

230


231 The patient was started on alpelisib daily dose of 350 mg orally<sup>7</sup> and he reported regression of  
232 his abdominal bulge within a few days. He reported no adverse events and was closely  
233 monitored for hyperglycemia. Repeated echocardiogram two months later showed normalization  
234 of the EF. A CT scan of the abdomen done six weeks into the trial revealed remarkable  
235 shrinkage of the LM (**Figure 2B**). Follow-up CT scans showed progressive reduction until  
236 complete response at one year of trial initiation (**Figure 2C**). The patient continued to do well on  
237 maintenance alpelisib for 2 years with no evidence of progression. After two years, alpelisib was  
238 discontinued due to theoretical concerns about long-term adverse impact on vascular

239 homeostasis. Unfortunately, the mass recurred after a few weeks so the patient was resumed  
240 on alpelisib with a second deep partial response, which is still ongoing for over three years.

241

### 242 **Alpelisib Inhibits Primary PI3K $\alpha$ -mutant Lymphatic Malformation-derived Endothelial** 243 **Cells**

244 We have also investigated the concentration-dependent effects of alpelisib on lymphatic  
245 malformation-lymphatic endothelial cells (LM-LECs) isolated from a surgically resected  
246 specimen<sup>8</sup>. Targeted sequencing of DNA from LM-LECs identified a somatic missense mutation  
247 in *PIK3CA* (H1047L), the same locus altered in our alpelisib-treated patient and the site of half  
248 of the *PIK3CA* alterations in the LM cohort studied (**Table 1**). In addition, a nonsense mutation  
249 of the regulatory PI3K unit *PIK3R3* (R309\*) was also detected in the CD31-positive LM-LECs  
250 and CD31-negative non-endothelial cells isolated from the same LM, indicating its germline  
251 origin<sup>8</sup>. We investigated the effect of alpelisib on the growth of LM-LECs and a concentration-  
252 dependent response curve was observed (**Figure 3**). The IC<sub>50</sub> of alpelisib against LM-LECs was  
253 empirically determined *in vitro* to be 4.72 x 10<sup>-9</sup> M at 24 hours. This *in vitro* translational model  
254 confirms the sensitivity of LM-derived human cells containing a target H1047<sup>R/L</sup> mutation to  
255 alpelisib.



256

257 **Figure 3. Alpelisib reduces LM-LEC viability.** (A) Logarithmic dose response curve of alpelisib was  
258 performed using the xCELLigence RTCA system. 1, 3, 10, 30 and 100 nM (5 replicates/concentration) of  
259 alpelisib were used to determine the concentration-response curve. The alpelisib half maximal inhibitory  
260 concentration (IC<sub>50</sub>) was calculated for LM-LEC at 24 h after treatment as 4.72 x 10<sup>-9</sup> M. (B) Illustrative  
261 picture of LM-LEC clonogenic plaques at 24 h after alpelisib treatment (4.72 x 10<sup>-9</sup> M). Negative, no  
262 treatment; dimethyl sulfoxide (DMSO), vehicle control. Experiments were performed two times with similar  
263 results. LM-LEC colonies were stained with crystal violet (0.3%). (C) Colony count 24 h after alpelisib  
264 treatment (4.72 x 10<sup>-9</sup> M).

265

## 266 Refined Genomic and Sequencing Analyses

267 We performed whole-genome sequencing (WGS) on paired LM/germline DNA from our index  
268 patient to explore the mutational profile beyond the genes that were probed in the Clinical  
269 Laboratory Improvement Amendments (CLIA)-approved clinical sequencing assay. The *PIK3CA*

270 H1047R mutation was identified with a Variant Allele Frequency (VAF) of 11%. This finding is  
271 consistent with the  $\leq 10\%$  rate of mutant cells, and low tumor cellularity of LMs with *PIK3CA*  
272 mutation<sup>2</sup>. Few other somatic coding mutations were identified in the LM tissue  
273 **(Supplementary Table 1)**.

274  
275 To gain further molecular mechanistic insight, we have also performed RNA-seq studies to  
276 identify gene expression patterns within the LM sample from our index patient. RNA-seq data of  
277 biopsy samples from Patient #9 (n=2 samples; Group A) was compared to several normal  
278 human control tissue samples from bladder, colon, kidney, and salivary gland (n=4, one sample  
279 per each tissue; Group B). By using an arbitrary cut-off of at least 2-fold up or down with  
280 adjusted *p*-values of 0.05 or less, we identified 668 up-regulated and 850 down-regulated  
281 genes. Several of the most highly induced genes, *CHI3L1*, *GPX1*, *PLIN1*, *PLIN4* and *JAK3*,  
282 have been linked to enhanced growth or cell survival in other tumor types<sup>9-13</sup>. Finally, a  
283 preliminary Gene Ontology (GO) analysis of Patient #9 LM revealed enrichment of mRNA of  
284 genes involved in vascular development, cell motility, inflammatory response, positive regulation  
285 of response to stimuli, blood vessel morphogenesis among others; notably, the kinase *JAK3*  
286 gene was one of the highest expression mRNAs in the LMs compared to normal tissue controls  
287 (data not shown).

288

289

## 290 **DISCUSSION**

291 Here we report the mutational landscape of a patient cohort of LMs (n=30 cases) which  
292 underwent comprehensive genomic profiling. We have confirmed prior reports that hotspot  
293 activating mutations in *PIK3CA* are common driver events in these lesions, seen in 20 (67%) of  
294 these cases. Interestingly *NRAS* mutations were seen in an additional 5 (17%) cases and were

295 particularly enriched in LMs with a kaposiform histopathology. This finding suggests that LMs  
296 with kaposiform features may represent a different pathologic entity<sup>14,15</sup>. As a caveat, for the  
297 one *NRAS* mutant LM with classic histology, the histologic classification was based on a small  
298 biopsy, and it is certainly possible that kaposiform histology was present in the large visceral LM  
299 but not captured by the limited sampling by core needle biopsy. Importantly, three of the five  
300 patients (60%) with *NRAS* mutant LMs had failed treatment with sirolimus prior to NGS. There  
301 are reports that some *NRAS*-mutant LMs may respond to treatment with MEK inhibitors<sup>16</sup>,  
302 suggesting this may be an option for LMs with kaposiform features.

303  
304 Of the 5 cases without either *PIK3CA* or *NRAS* mutations, all of classic histology, a single case  
305 had a known pathogenic in-frame *GOPC-ROS1* genetic fusion predicted to have an intact ROS1  
306 kinase domain and thus potentially function as the driver. Similar *GOPC-ROS1* fusions have  
307 been seen in pediatric gliomas and adult lung cancers and may be sensitive to ROS1  
308 inhibitors<sup>5,6</sup>. These data suggest that most LMs may have a potentially actionable driver  
309 mutation, with *PIK3CA* mutations dominating LMs with conventional histology and *NRAS*  
310 mutations predominantly or exclusively seen in the minor subset of LMs with kaposiform  
311 features. It is possible that the other *NRAS* and *KRAS* wild-type LMs may also have oncogenic  
312 alterations in other members of the *PIK3CA* or MAPK signaling pathway members that were not  
313 profiled by targeted sequencing strategies. Comprehensive NGS analysis of LMs with *PIK3CA*  
314 and *NRAS* wild-type may be required to identify any potential actionable driver mutations. In  
315 patients without solid LM tissue available for NGS, liquid biopsy--or NGS performed on  
316 circulating tumor DNA (ctDNA) in peripheral blood--may be a possible solution for LMs, which  
317 are innately associated with the vascular system and thus potentially "shedding" ctDNA into the  
318 peripheral blood.

319

320 To illustrate the potential for therapeutic intervention of the target mutations identified, we  
321 performed an N-of-1 trial of alpelisib in one young adult index patient with a giant retroperitoneal  
322 and pancreatic LM with conventional histological features and a gain-of-function H1047R  
323 somatic *PIK3CA* mutation. Our index patient experienced a rapid, complete, and durable clinical  
324 response with this small molecule PI3K $\alpha$  inhibitor. Given the high frequency of *PIK3CA*  
325 mutations in pediatric LMS<sup>2</sup>, this finding suggests that alpelisib may be highly effective for  
326 systemic, non-surgical treatment approach to this class of disorders. Furthermore, the lack of  
327 toxicity to alpelisib in our case is promising in terms of a potential future treatment of young  
328 patients with LMs. Our patient did not experience increases in glucose levels, consistent with  
329 reported lack of alpelisib-induced hyperglycemia in most pediatric patients with PROS<sup>17,18</sup>. In  
330 this prior series, only one patient developed new-onset hyperglycemia and this was controlled  
331 by dietary modification<sup>17</sup>. These findings suggest that the effect of alpelisib on inducing  
332 hyperglycemia might perhaps be less of a concern in younger patients, who may have more  
333 robust glucose homeostasis, compared with older patients who may already have subclinical  
334 insulin-resistance.

335

336 Ultimately, we decided to hold alpelisib after two years of complete radiological response, and  
337 unfortunately the LM relapsed but the patient still achieved a major partial response on the  
338 second challenge with alpelisib. This result suggests that PI3K $\alpha$  inhibitors do not completely  
339 eradicate all LM-initiating cells, and they may need to be given long-term (in our young index  
340 patient case, perhaps over decades) in *PIK3CA* mutant LMs for sustained control. This class of  
341 drugs can also be envisioned to be utilized in a neoadjuvant approach to render large cases  
342 resectable. Our patient declined surgery after initial response and he continues on alpelisib for  
343 several years. Acquired resistance mechanisms to PI3K $\alpha$  inhibitors have been reported, due to  
344 other associated compensatory or bypassing mutations such as ones involving *RAS* oncogene<sup>19</sup>



345 or *PTEN* tumor suppressor gene<sup>20</sup>, and these may conceivably arise in these patients with  
346 longer follow up over time. Deftly balancing the potential benefits of continuing treatment with  
347 the potential for drug resistance mechanisms will require monitoring for both actionable known  
348 and novel mutations through NGS of LM tissue samples or liquid biopsy.

349  
350 In a series of pediatric patients with LMs, Luks et al. identified *PIK3CA* gene mutations in  
351 patients with sporadic LMs in 16 out of 17 patients (94%) or syndromic LMs such as the Klippel-  
352 Trenaunay syndrome in 19 out of 21 patients (90%), fibro-adipose vascular anomaly in 5 out of  
353 8 patients (63%), along with the CLOVES syndrome in 31 out of 33 patients (94%)<sup>2</sup>. H1047R  
354 was one of the top two most frequently encountered hotspot mutations in this series. Venot et  
355 al. reported a single arm clinical trial of alpelisib in 19 patients with pediatric PROS including  
356 CLOVES<sup>17</sup>. Alpelisib treatment induced clinical responses in all patients, including improvement  
357 of cardiac EF as seen in our index patient. Of note, alpelisib induced responses in patients who  
358 did not respond to prior treatment with mTOR inhibitors, such as rapamycin, similar to  
359 observations in *KRAS* mutant oncology patients<sup>21</sup>. Small clinical series have shown that mTOR  
360 inhibition can induce responses in a subset of unselected advanced LMs, with observed  
361 response rates of ~50-60%<sup>22</sup>. The on driver-oncoprotein activity, higher response rates, and  
362 tolerability suggests alpelisib may be more effective than mTOR inhibitors in this setting. It is  
363 tempting to speculate that a wide variety of *PIK3CA* mutant somatic overgrowth conditions<sup>23</sup>  
364 may be amenable to medical treatment with FDA-approved PI3K $\alpha$  inhibitors, either as neo-  
365 adjuvant treatment in potentially resectable cases, or as primary treatment in unresectable  
366 cases<sup>7,20,24-26</sup>.

367  
368 Furthermore, in our Whole Genome Sequencing (WGS) analysis, we identified only a few  
369 somatic variants within protein-coding genetic sequences (**Supplementary Table 1**) beyond

370 what was reported in the cancer gene panel (**Table 1**). The low frequency of somatic mutations  
371 is consistent with findings in other low-grade pediatric tumors<sup>27</sup>. In addition to detecting the  
372 *PIK3CA* H1047R mutation, this WGS confirmed the variant detected by the cancer gene panel  
373 in the *PIK3C2B* gene and demonstrated that it was germline. Although this in *PIK3C2B* variant  
374 has not been characterized and may be a benign polymorphism, this finding raises the issue of  
375 whether other alterations in the pathway may cooperate with activating mutations of *PIK3CA* to  
376 induce cell proliferation. The low VAF driver mutations in tissue derived from LMs is likely due to  
377 the fact that most pathological tissue is composed of reactive stromal elements while the clonal  
378 cells represent a relatively small portion (presumably the lymphatic channel-lining endothelial  
379 cells). Consistent with this observation, in the alpelisib-treated index patient, we observed most  
380 intense activation of the PI3K $\alpha$  pathway in these lymphatic channel-lining endothelial cells  
381 (**Figure 2 F,G**). The high representations of pathways associated with vascular development,  
382 cell motility, inflammatory response, positive regulation of response to stimuli, blood vessel  
383 morphogenesis in our gene expression analysis is consistent with a mechanistic hypothesis that  
384 most of the lesion represents an intense reactive response to the (presumably) clonal LM-LECs,  
385 although the appropriate comparator control tissues for these lesions is not clear.

386


387 Evidence is accumulating that a variety of “non-malignant” syndromes associated with abnormal  
388 tissue growth may be driven by underlying alterations in classic oncogenes<sup>28</sup>. *PIK3CA* mutations  
389 are seen not only in LMs but other vascular anomalies, highlighting the role of *PIK3CA*  
390 activation in angiogenesis, lymphangiogenesis and vascular neoplasms<sup>29-31 32</sup>. Endometriosis,  
391 uterine fibroids and seborrheic keratoses all have been found to harbor mutations in cancer  
392 related genes<sup>33-37</sup>. These findings suggest that targeted therapies being developed for invasive  
393 cancers may also be active in proliferative lesions that are not classified as invasive cancers  
394 that harbor the targeted alteration.



395

396 In summary (**Figure 4**), we find that the majority of LMs have driver mutations that are  
397 potentially targetable. LMs with classic histology mostly have *PIK3CA* mutations that may  
398 respond to alpelisib. LMs with kaposiform histopathology are enriched in *NRAS* mutations, and  
399 studies are required to determine if these may respond to clinically available MEK inhibitors.  
400 LMs that are wild-type for *PIK3CA* and *NRAS* may have other actionable alterations, such as  
401 the *GOPC-ROS1* fusion seen in our series and may require more comprehensive genomic  
402 analyses to identify them. Systemic treatment with targeted therapy aimed at the driver mutation  
403 in LMs may be an option for some patients who are not controlled by surgery and other  
404 conventional treatments.

405



406 **Figure 4. Graphical summary of the mutations found in genomic analysis of LM patient cohort**  
407 **(Created with BioRender.com).** (A) The majority of LMs have driver mutations that are potentially  
408 targetable. (B) LMs with *NRAS* mutations had kaposiform histopathology. (C) An N-of-1 clinical trial is  
409 reported in a patient with a targetable *PIK3CA* mutation. (D) Comprehensive genomic analyses may  
410 reveal further actionable molecular insights.

411 **METHODS**

412 **Genomics and DNA Sequencing.** Hybrid-capture DNA sequencing targeting exons of at least  
413 324 cancer genes and select introns of 36 genes were performed on the patient samples; a  
414 subset (n=2) were also analyzed with plus RNA sequencing of 265 genes to improve  
415 rearrangement detection. A total of 30 patient samples were sequenced with either the DNA-  
416 only assay (n=28; Foundation One CDx, Foundation Medicine; Cambridge, MA) or the  
417 DNA+RNA assay (n=2; Foundation One Heme, Foundation Medicine; Cambridge, MA).

418

419 **Immunohistochemistry.** Immunohistochemistry (IHC) was performed on formalin-fixed,  
420 deparaffinized, 5-micron thick sections mounted on charged slides. Antibodies to P-AKT  
421 (Ser473), and P-6S (Ser240/Ser244) were obtained from Cell Signaling Technology, Danvers,  
422 Massachusetts. Diaminobenzidine (DAB) was used as the chromogen and hematoxylin as the  
423 counterstain. All stages of staining were carried out on an automated system (Ventana  
424 Discovery Research Instrument; Ventana, Tucson, Arizona). Positive and negative controls  
425 were appropriately reactive. A surgical pathologist with subspecialty interest in musculoskeletal  
426 pathology (T.J.B.) interpreted the results.

427

428 **LM-LEC Sensitivity to Alpelisib In Vitro.** LM-LEC cells were maintained as described <sup>8</sup> and  
429 negative for mycoplasma at the time of these studies. Mycoplasma test was performed using  
430 the MycoAlert Mycoplasma Detection Kit (Cat # LT07-218, Lonza) following the manufacturer's  
431 instructions. Real-time analysis of cell viability was performed by using the xCELLigence system  
432 RTCA SP (ACEA Biosciences). Briefly,  $5 \times 10^3$  LM-LECs per well were seeded in an E-Plate 96  
433 (ACEA Biosciences) and cell proliferation was recorded hourly. When the cells reached the  
434 exponential growth phase, new media containing alpelisib at 1, 3, 10, 30, or 100 nM was added

435 and alpelisib cytotoxic effect was recorded hourly. IC<sub>50</sub> was calculated by using the Dose-  
436 Response Curve (DRC) function available in the xCELLigence software Version 2.0. Cell index  
437 (%) reflects cell viability.

438

439 **Clonogenic Survival Assays.** For the clonogenic survival assay, the LM-LEC were trypsinized,  
440 counted and plated in complete growth media on 6-well plates (Falcon) (400 cells/well). Seven  
441 days later, alpelisib (at the empirically determined IC<sub>50</sub> from a standard calibration curve) was  
442 added in duplicate wells. After 24 h or 48 h of incubation, cells were fixed and stained in 50%  
443 methanol in water containing 0.3% crystal violet to facilitate counting of colonies (≥50 cells).

444

445 **Statistics.** All values are expressed as mean with error bars expressed as SD. For comparison  
446 between untreated (negative), DMSO control, and Alpelisib treated LM-LEC cells, the ordinary  
447 one-way ANOVA and Tukey's multiple comparisons test with a single pooled variance were  
448 used. Statistical analysis was performed using the Graph Pad Prism 7.0d software (GraphPad  
449 Software Inc., San Diego, CA, USA). Fisher's exact test was used for categorical data, owing to  
450 the sizes of the cohorts. A two-tailed P value of <0.05 was considered to be statistically  
451 significant.

452

453 **Study approval.** Approval for this study, including a waiver of informed consent and Health  
454 Insurance Portability and Accountability Act waiver of authorization, was obtained from the  
455 Western Institutional Review Board (IRB; protocol #20152817). A single-institution personalized  
456 clinical protocol to treat the patient with the experimental PI3K $\alpha$  inhibitor alpelisib was  
457 scientifically reviewed by the Protocol Review and Monitoring Committee (PRMC) and approved  
458 by the local Institutional Review Board (IRB) of the University of New Mexico Comprehensive

459 Cancer Center. The study (NCT03941782) was conducted in accordance with the protocol,  
460 Good Clinical Practice guidelines, and the provisions of the Declaration of Helsinki. CARE  
461 reporting guidelines were also used for this patient<sup>38</sup>. The index patient signed an informed  
462 written consent form.  
463

464 **Author contributions:** Conceptualization: MFS, JYT, ESS, MM, RP, SG, WA; Methodology:  
465 MFS, JYT, ESS, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG, JEB, SAN, GMR, RG; Investigation:  
466 MFS, JYT, ESS, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG, JEB, SAN, GMR, RG; Visualization:  
467 MFS, JYT, ESS, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG, JEB, SAN, GMR, RG; Funding  
468 acquisition: MFS, MM, RP, SG, WA; Project administration: MFS, JYT, RP, SG, WA;  
469 Supervision: MFS, JYT, RP, SG, WA; Writing – original draft: MFS, JYT, ESS, RP, SG, WA;  
470 Writing – review & editing: MFS, JYT, ESS, MM, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG,  
471 JEB, SAN, GMR, RG, RP, SG, WA

472

473 **Acknowledgments:** We thank Dr. Kathryn J. Brayer for technical assistance and Dr. Helen  
474 Pickersgill (Life Science Editors) for professional manuscript editing services.

475

476 **Funding:** R.P. and W.A. are supported by awards from the Levy-Longenbaugh Fund. S.G. is  
477 supported by awards from the Hugs for Brady Foundation. This work has been funded in part by  
478 the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center  
479 (CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the  
480 Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science  
481 Foundation via Graduate Research Fellowship DGE-1143953.

482

483

484

485 **References**

- 486 1. Perkins JA, Manning SC, Tempero RM, Cunningham MJ, Edmonds JL, Jr., Hoffer FA,  
487 Egbert MA. Lymphatic malformations: review of current treatment. *Otolaryngol Head*  
488 *Neck Surg.* 2010;142(6):795-803, 803 e791. doi: 10.1016/j.otohns.2010.02.026
- 489 2. Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, Rialon KL, Guevara CJ,  
490 Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB,  
491 Rahbar R, Spencer SA, Trenor CC, 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A,  
492 Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R. Lymphatic  
493 and other vascular malformative/overgrowth disorders are caused by somatic mutations  
494 in PIK3CA. *J Pediatr.* 2015;166(4):1048-1054 e1041-1045. doi:  
495 10.1016/j.jpeds.2014.12.069
- 496 3. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K  
497 Pathway in Human Disease. *Cell.* 2017;170(4):605-635. doi: 10.1016/j.cell.2017.07.029
- 498 4. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell  
499 SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.  
500 High frequency of mutations of the PIK3CA gene in human cancers. *Science.*  
501 2004;304(5670):554. doi: 10.1126/science.1096502
- 502 5. Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar  
503 R, Gilheeneey SW, DeCarvalo A, Mikkelson T, Van Meir EG, Ladanyi M, Druker BJ. Rare  
504 but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are  
505 Targetable Oncogenes in Glioma. *Clin Cancer Res.* 2018;24(24):6471-6482. doi:  
506 10.1158/1078-0432.CCR-18-1052
- 507 6. Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent  
508 cancers - biology, diagnostics and therapeutics. *Nat Rev Clin Oncol.* 2021;18(1):35-55.  
509 doi: 10.1038/s41571-020-0408-9
- 510 7. Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR,  
511 Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D,  
512 Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3-  
513 Kinase alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid  
514 Tumors: Results From the First-in-Human Study. *J Clin Oncol.* 2018;36(13):1291-1299.  
515 doi: 10.1200/JCO.2017.72.7107
- 516 8. Boscolo E, Coma S, Luks VL, Greene AK, Klagsbrun M, Warman ML, Bischoff J. AKT  
517 hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells  
518 from a patient with lymphatic malformation. *Angiogenesis.* 2015;18(2):151-162. doi:  
519 10.1007/s10456-014-9453-2
- 520 9. Cheng Y, Xu T, Li S, Ruan H. GPX1, a biomarker for the diagnosis and prognosis of  
521 kidney cancer, promotes the progression of kidney cancer. *Aging (Albany NY).*  
522 2019;11(24):12165-12176. doi: 10.18632/aging.102555
- 523 10. Qiu QC, Wang L, Jin SS, Liu GF, Liu J, Ma L, Mao RF, Ma YY, Zhao N, Chen M, Lin BY.  
524 CHI3L1 promotes tumor progression by activating TGF-beta signaling pathway in  
525 hepatocellular carcinoma. *Sci Rep.* 2018;8(1):15029. doi: 10.1038/s41598-018-33239-8

- 526 11. Siros I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot  
527 C, Ramanathan A, Balachandran B, Legare S, Przybytkowski E, Lan C, Krzemien U,  
528 Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-  
529 Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi  
530 RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA,  
531 Mihalcioiu C, Majewski J, Basik M. A Unique Morphological Phenotype in  
532 Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and  
533 PLIN4 Expression as a Molecular Vulnerability. *Mol Cancer Res.* 2019;17(12):2492-  
534 2507. doi: 10.1158/1541-7786.MCR-19-0264
- 535 12. Vadivel CK, Gluud M, Torres-Rusillo S, Boding L, Willerslev-Olsen A, Buus TB, Nielsen  
536 TK, Persson JL, Bonfeld CM, Geisler C, Krejsgaard T, Fuglsang AT, Odum N,  
537 Woetmann A. JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T  
538 Cell Lymphoma (CTCL). *Cancers (Basel).* 2021;13(2). doi: 10.3390/cancers13020280
- 539 13. Zhang Q, Zhang P, Li B, Dang H, Jiang J, Meng L, Zhang H, Zhang Y, Wang X, Li Q,  
540 Wang Y, Liu C, Li F. The Expression of Perilipin Family Proteins can be used as  
541 Diagnostic Markers of Liposarcoma and to Differentiate Subtypes. *J Cancer.*  
542 2020;11(14):4081-4090. doi: 10.7150/jca.41736
- 543 14. Barclay SF, Inman KW, Luks VL, McIntyre JB, Al-Ibraheemi A, Church AJ, Perez-Atayde  
544 AR, Mangray S, Jeng M, Kreimer SR, Walker L, Fishman SJ, Alomari AI, Chaudry G,  
545 Trenor Iii CC, Adams D, Kozakewich HPW, Kurek KC. A somatic activating NRAS  
546 variant associated with kaposiform lymphangiomatosis. *Genet Med.* 2019;21(7):1517-  
547 1524. doi: 10.1038/s41436-018-0390-0
- 548 15. Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G,  
549 Mulliken JB, Trenor CC, 3rd. Kaposiform lymphangiomatosis: a distinct aggressive  
550 lymphatic anomaly. *J Pediatr.* 2014;164(2):383-388. doi: 10.1016/j.jpeds.2013.10.013
- 551 16. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM,  
552 Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C,  
553 Hogg D, Liskay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V,  
554 Bozon V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with  
555 advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised,  
556 phase 3 trial. *Lancet Oncol.* 2017;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8
- 557 17. Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC,  
558 Huguin C, Boccara O, Samacki S, Boddaert N, Pannier S, Martinez F, Magassa S,  
559 Yamaguchi J, Knebelmann B, Merville P, Grenier N, Joly D, Cormier-Daire V, Michot C,  
560 Bole-Feysot C, Picard A, Soupre V, Lyonnet S, Sadoine J, Slimani L, Chaussain C,  
561 Laroche-Raynaud C, Guibaud L, Broissand C, Amiel J, Legendre C, Terzi F, Canaud G.  
562 Targeted therapy in patients with PIK3CA-related overgrowth syndrome. *Nature.*  
563 2018;558(7711):540-546. doi: 10.1038/s41586-018-0217-9
- 564 18. Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D,  
565 Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. A Phase Ib Study  
566 of Alpelisib (BYL719), a PI3Kalpha-Specific Inhibitor, with Letrozole in ER+/HER2-  
567 Metastatic Breast Cancer. *Clin Cancer Res.* 2017;23(1):26-34. doi: 10.1158/1078-  
568 0432.CCR-16-0134



- 569 19. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM,  
570 Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ,  
571 Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR  
572 inhibitors. *Cell Rep.* 2014;6(2):377-387. doi: 10.1016/j.celrep.2013.12.035
- 573 20. Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage  
574 HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J.  
575 Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with  
576 Advanced Solid Tumors. *Cancer Discov.* 2017;7(7):704-715. doi: 10.1158/2159-  
577 8290.CD-16-1080
- 578 21. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M,  
579 Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini  
580 M, Baselga J, Gallicchio M, Biffo S, Bardelli A. Deregulation of the PI3K and KRAS  
581 signaling pathways in human cancer cells determines their response to everolimus. *J*  
582 *Clin Invest.* 2010;120(8):2858-2866. doi: 10.1172/JCI37539
- 583 22. Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, Costa J, Ferreira J.  
584 Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic  
585 review. *J Vasc Surg.* 2020;71(1):318-327. doi: 10.1016/j.jvs.2019.06.217
- 586 23. Huchtagowder V, Shenoy A, Corliss M, Vigh-Conrad KA, Storer C, Grange DK, Cottrell  
587 CE. Utility of clinical high-depth next generation sequencing for somatic variant detection  
588 in the PIK3CA-related overgrowth spectrum. *Clin Genet.* 2017;91(1):79-85. doi:  
589 10.1111/cge.12819
- 590 24. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birlle D, Demanse D, De Buck  
591 SS, Ru QC, Peters M, Goldbrunner M, Baselga J. Phase I, dose-escalation study of  
592 BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. *J*  
593 *Clin Oncol.* 2012;30(3):282-290. doi: 10.1200/JCO.2011.36.1360
- 594 25. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo  
595 AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno  
596 A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase  
597 inhibitor, in patients with advanced solid tumors. *Clin Cancer Res.* 2012;18(15):4173-  
598 4182. doi: 10.1158/1078-0432.CCR-12-0714
- 599 26. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ,  
600 Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A,  
601 Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis  
602 ER, Berger MF, Baselga J, Scaltriti M. Convergent loss of PTEN leads to clinical  
603 resistance to a PI(3)Kalpha inhibitor. *Nature.* 2015;518(7538):240-244. doi:  
604 10.1038/nature13948
- 605 27. Akhavanfard S, Padmanabhan R, Yehia L, Cheng F, Eng C. Comprehensive germline  
606 genomic profiles of children, adolescents and young adults with solid tumors. *Nat*  
607 *Commun.* 2020;11(1):2206. doi: 10.1038/s41467-020-16067-1
- 608 28. Mustjoki S, Young NS. Somatic Mutations in "Benign" Disease. *N Engl J Med.*  
609 2021;384(21):2039-2052. doi: 10.1056/NEJMra2101920



- 610 29. Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, Bague S,  
611 Scaltriti M, Antonescu CR, Baselga E, Baselga J. Somatic PIK3CA mutations as a driver  
612 of sporadic venous malformations. *Sci Transl Med*. 2016;8(332):332ra342. doi:  
613 10.1126/scitranslmed.aaf1164
- 614 30. Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjano IM, Parker VE, Chivite I, Mila-  
615 Guasch M, Pearce W, Solomon I, Angulo-Urarte A, Figueiredo AM, Dewhurst RE, Knox  
616 RG, Clark GR, Scudamore CL, Badar A, Kalber TL, Foster J, Stuckey DJ, David AL,  
617 Phillips WA, Lythgoe MF, Wilson V, Semple RK, Sebire NJ, Kinsler VA, Graupera M,  
618 Vanhaesebroeck B. Somatic activating mutations in *Pik3ca* cause sporadic venous  
619 malformations in mice and humans. *Sci Transl Med*. 2016;8(332):332ra343. doi:  
620 10.1126/scitranslmed.aad9982
- 621 31. Limaye N, Kangas J, Mendola A, Godfraind C, Schlogel MJ, Helaers R, Eklund L, Boon  
622 LM, Vikkula M. Somatic Activating PIK3CA Mutations Cause Venous Malformation. *Am J*  
623 *Hum Genet*. 2015;97(6):914-921. doi: 10.1016/j.ajhg.2015.11.011
- 624 32. Ren AA, Snellings DA, Su YS, Hong CC, Castro M, Tang AT, Detter MR, Hobson N,  
625 Girard R, Romanos S, Lightle R, Moore T, Shenkar R, Benavides C, Beaman MM,  
626 Müller-Fielitz H, Chen M, Mericko P, Yang J, Sung DC, Lawton MT, Ruppert JM,  
627 Schwaninger M, Körbelin J, Potente M, Awad IA, Marchuk DA, Kahn ML. PIK3CA and  
628 CCM mutations fuel cavernomas through a cancer-like mechanism. *Nature*. 2021. doi:  
629 10.1038/s41586-021-03562-8
- 630 33. Rafnar T, Gunnarsson B, Stefansson OA, Sulem P, Ingason A, Frigge ML, Stefansdottir  
631 L, Sigurdsson JK, Tragante V, Steinthorsdottir V, Styrkarsdottir U, Stacey SN,  
632 Gudmundsson J, Amadottir GA, Oddsson A, Zink F, Halldorsson G, Sveinbjornsson G,  
633 Kristjansson RP, Davidsson OB, Salvardsdottir A, Thoroddsen A, Helgadottir EA,  
634 Kristjansdottir K, Ingthorsson O, Gudmundsson V, Geirsson RT, Arnadottir R,  
635 Gudbjartsson DF, Masson G, Asselbergs FW, Jonasson JG, Olafsson K,  
636 Thorsteinsdottir U, Halldorsson BV, Thorleifsson G, Stefansson K. Variants associating  
637 with uterine leiomyoma highlight genetic background shared by various cancers and  
638 hormone-related traits. *Nat Commun*. 2018;9(1):3636. doi: 10.1038/s41467-018-05428-6
- 639 34. Gallagher CS, Makinen N, Harris HR, Rahmioglu N, Uimari O, Cook JP, Shigeshi N,  
640 Ferreira T, Velez-Edwards DR, Edwards TL, Mortlock S, Ruhioğlu Z, Day F, Becker CM,  
641 Karhunen V, Martikainen H, Jarvelin MR, Cantor RM, Ridker PM, Terry KL, Buring JE,  
642 Gordon SD, Medland SE, Montgomery GW, Nyholt DR, Hinds DA, Tung JY, andMe  
643 Research T, Perry JRB, Lind PA, Painter JN, Martin NG, Morris AP, Chasman DI,  
644 Missmer SA, Zondervan KT, Morton CC. Genome-wide association and epidemiological  
645 analyses reveal common genetic origins between uterine leiomyomata and  
646 endometriosis. *Nat Commun*. 2019;10(1):4857. doi: 10.1038/s41467-019-12536-4
- 647 35. Fritsche LG, Gruber SB, Wu Z, Schmidt EM, Zawistowski M, Moser SE, Blanc VM,  
648 Brummett CM, Kheterpal S, Abecasis GR, Mukherjee B. Association of Polygenic Risk  
649 Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan  
650 Genomics Initiative. *Am J Hum Genet*. 2018;102(6):1048-1061. doi:  
651 10.1016/j.ajhg.2018.04.001
- 652 36. Sanders MGH, Pardo LM, Uitterlinden AG, Smith AM, Ginger RS, Nijsten T. The  
653 Genetics of Seborrheic Dermatitis: A Candidate Gene Approach and Pilot Genome-Wide

- 654 Association Study. *J Invest Dermatol*. 2018;138(4):991-993. doi:  
655 10.1016/j.jid.2017.11.020
- 656 37. Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noe M, Horlings HM, Lum A,  
657 Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan  
658 R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M,  
659 McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N,  
660 Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM.  
661 Cancer-Associated Mutations in Endometriosis without Cancer. *N Engl J Med*.  
662 2017;376(19):1835-1848. doi: 10.1056/NEJMoa1614814
- 663 38. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, Group C. The CARE  
664 guidelines: consensus-based clinical case reporting guideline development. *BMJ Case*  
665 *Rep*. 2013;2013. doi: 10.1136/bcr-2013-201554
- 666
- 667

668 **Supplementary Table 1. Somatic coding mutations identified from whole genome**  
 669 **sequencing**

Gene_Name	Protein_Change	VAF	alt_depth	ref_depth	COSMIC
HRNR 0.105	p.T616A	0.105	4	51	
OR2T3	p.S247F	0.171	8	53	
PLXDC2	p.V396I	0.167	4	22	
FOLH1	p.R190W	0.333	8	20	
IPO8	p.M488fs	0.125	3	28	
KRR1	p.R134Q	0.188	3	17	
KRTAP4-11	p.L161V	0.116	9	49	
TTYH1	p.E440fs	0.130	6	31	
TTYH1	p.440_441insH	0.130	6	30	
KIF5C	p.K151fs	0.200	3	16	
LY75-CD302	p.T1393I	0.188	3	18	
BARD1	p.P24S	0.087	4	59	
KRTAP10-12	p.P92S	0.133	5	38	
NFXL1	p.P246L	0.176	3	20	
PLA2G7	p.R92H	0.188	3	18	
NAT2	p.R268K	0.200	7	28	p.R268K
AQP7	p.Y64F	0.068	7	88	
KIAA1984	p.N421T	0.125	4	42	

670 The genetic coding variants that exist in LM but do not exist in germline DNA. These pass MuTect2 quality  
 671 filters (designed to call somatic variants only) and have three or more alternate reads. VAF, Variant Allele  
 672 Frequency; COSMIC, Catalogue Of Somatic Mutations In Cancer.  
 673